{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:20:49Z","timestamp":1780579249143,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00280-018-3526-7","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T22:34:58Z","timestamp":1517351698000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["2-Deoxy-d-glucose enhances TRAIL-induced apoptosis in human gastric cancer cells through downregulating JNK-mediated cytoprotective autophagy"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7640-4018","authenticated-orcid":false,"given":"Yuting","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maojin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"issue":"2","key":"3526_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. Cancer J Clin 65(2):87\u2013108. \n                    https:\/\/doi.org\/10.3322\/caac.21262","journal-title":"Cancer J Clin"},{"issue":"5309","key":"3526_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1126\/science.276.5309.111","volume":"276","author":"G Pan","year":"1997","unstructured":"Pan G, O\u2019Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276(5309):111\u2013113","journal-title":"Science"},{"issue":"18","key":"3526_CR3","doi-asserted-by":"publisher","first-page":"14402","DOI":"10.1016\/j.cell.2005.07.002","volume":"287","author":"MAPE Laussmann","year":"2012","unstructured":"Laussmann MAPE., Hellwig CT, Tomiczek B, Flanagan L, Prehn JH, Huber HJ, Rehm M (2012) Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling. J Biol Chem 2012 Apr 27 287(18):14402\u201314411 (6). \n                    https:\/\/doi.org\/10.1016\/j.cell.2005.07.002","journal-title":"J Biol Chem 2012 Apr"},{"issue":"4","key":"3526_CR4","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-09-1267","volume":"16","author":"DR Camidge","year":"2010","unstructured":"Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clinical cancer research.Off J Am Assoc Cancer Res 16(4):1256\u20131263. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1267","journal-title":"Off J Am Assoc Cancer Res"},{"issue":"33","key":"3526_CR5","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1200\/JCO.2011.37.2623","volume":"29","author":"JC Soria","year":"2011","unstructured":"Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E, Pujol JL, Kozielski J, Baker N, Smethurst D, Hei YJ, Ashkenazi A, Stern H, Amler L, Pan Y, Blackhall F (2011) Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(33):4442\u20134451. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.37.2623","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7","key":"3526_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.bjc.6600547","volume":"87","author":"RL Aft","year":"2002","unstructured":"Aft RL, Zhang FW, Gius D (2002) Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br J Cancer 87(7):805\u2013812. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600547","journal-title":"Br J Cancer"},{"key":"3526_CR7","doi-asserted-by":"publisher","first-page":"8726","DOI":"10.1038\/srep08726","volume":"5","author":"N Kaushik","year":"2015","unstructured":"Kaushik N, Lee SJ, Choi TG, Baik KY, Uhm HS, Kim CH, Kaushik NK, Choi EH (2015) Non-thermal plasma with 2-deoxy-D-glucose synergistically induces cell death by targeting glycolysis in blood cancer cells. Sci Rep 5:8726. \n                    https:\/\/doi.org\/10.1038\/srep08726","journal-title":"Sci Rep"},{"key":"3526_CR8","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1038\/cddis.2013.60","volume":"4","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Butler EB, Tan M (2013) Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Cell Death Dis 4:e532. \n                    https:\/\/doi.org\/10.1038\/cddis","journal-title":"Cell Death Dis"},{"key":"3526_CR9","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1476-4598-8-122","volume":"8","author":"H Liu","year":"2009","unstructured":"Liu H, Jiang CC, Lavis CJ, Croft A, Dong L, Tseng HY, Yang F, Tay KH, Hersey P, Zhang XD (2009) 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol Cancer 8:122. \n                    https:\/\/doi.org\/10.1186\/1476-4598-8-122","journal-title":"Mol Cancer"},{"issue":"5","key":"3526_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4161\/auto.7.5.15066","volume":"7","author":"TR O\u2019Donovan","year":"2011","unstructured":"O\u2019Donovan TR, O\u2019Sullivan GC, McKenna SL (2011) Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 7(5):509\u2013524","journal-title":"Autophagy"},{"issue":"4","key":"3526_CR11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2011.10.026","volume":"147","author":"N Mizushima","year":"2011","unstructured":"Mizushima N, Komatsu M (2011) Autophagy: renovation of cells and tissues. Cell 147(4):728\u2013741. \n                    https:\/\/doi.org\/10.1016\/j.cell.2011.10.026","journal-title":"Cell"},{"issue":"9","key":"3526_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.18632\/oncotarget.1174","volume":"4","author":"X Di","year":"2013","unstructured":"Di X, Zhang G, Zhang Y, Takeda K, Rivera Rosado LA, Zhang B (2013) Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5. Oncotarget 4(9):1349\u20131364. \n                    https:\/\/doi.org\/10.18632\/oncotarget.1174","journal-title":"Oncotarget"},{"issue":"5","key":"3526_CR13","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/glia.20785","volume":"57","author":"R Mora","year":"2009","unstructured":"Mora R, Abschuetz A, Kees T, Dokic I, Joschko N, Kleber S, Geibig R, Mosconi E, Zentgraf H, Martin-Villalba A, Regnier-Vigouroux A (2009) TNF-alpha- and TRAIL-resistant glioma cells undergo autophagy-dependent cell death induced by activated microglia. Glia 57(5):561\u2013581. \n                    https:\/\/doi.org\/10.1002\/glia.20785","journal-title":"Glia"},{"issue":"6","key":"3526_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.molcel.2008.06.001","volume":"30","author":"Y Wei","year":"2008","unstructured":"Wei Y, Pattingre S, Sinha S, Bassik M, Levine B (2008) JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Molecular cell 30(6):678\u2013688. \n                    https:\/\/doi.org\/10.1016\/j.molcel.2008.06.001","journal-title":"Molecular cell"},{"issue":"4","key":"3526_CR15","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.bbrc.2009.03.095","volume":"382","author":"KJ Park","year":"2009","unstructured":"Park KJ, Lee SH, Lee CH, Jang JY, Chung J, Kwon MH, Kim YS (2009) Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. Biochem Biophys Res Commun 382(4):726\u2013729. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2009.03.095","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"3526_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.febslet.2009.02.014","volume":"583","author":"L Xu","year":"2009","unstructured":"Xu L, Qu X, Zhang Y, Hu X, Yang X, Hou K, Teng Y, Zhang J, Sada K, Liu Y (2009) Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett 583(5):943\u2013948. \n                    https:\/\/doi.org\/10.1016\/j.febslet.2009.02.014","journal-title":"FEBS Lett"},{"issue":"4","key":"3526_CR17","doi-asserted-by":"publisher","first-page":"E337-347","DOI":"10.1002\/ijc.26420","volume":"131","author":"AM Giammarioli","year":"2012","unstructured":"Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M, Gnessi L, Griffin RJ, Minetti M, Malorni W (2012) Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. Int J Cancer J Int Du Cancer 131(4):E337-347. \n                    https:\/\/doi.org\/10.1002\/ijc.26420","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"23","key":"3526_CR18","doi-asserted-by":"publisher","first-page":"3364","DOI":"10.1038\/sj.onc.1210134","volume":"26","author":"BM Kurbanov","year":"2007","unstructured":"Kurbanov BM, Fecker LF, Geilen CC, Sterry W, Eberle J (2007) Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Oncogene 26(23):3364\u20133377. \n                    https:\/\/doi.org\/10.1038\/sj.onc.1210134","journal-title":"Oncogene"},{"issue":"24","key":"3526_CR19","doi-asserted-by":"publisher","first-page":"21164","DOI":"10.1074\/jbc.M110.207571","volume":"286","author":"Z Li","year":"2011","unstructured":"Li Z, Xu X, Bai L, Chen W, Lin Y (2011) Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem 286(24):21164\u201321172. \n                    https:\/\/doi.org\/10.1074\/jbc.M110.207571","journal-title":"J Biol Chem"},{"issue":"11","key":"3526_CR20","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1038\/jid.2015.250","volume":"135","author":"SA Quast","year":"2015","unstructured":"Quast SA, Steinhorst K, Plotz M, Eberle J (2015) Sensitization of melanoma cells for death ligand trail is based on cell cycle arrest, ros production, and activation of proapoptotic Bcl-2 Proteins. J Investig Dermatol 135(11):2794\u20132804. \n                    https:\/\/doi.org\/10.1038\/jid.2015.250","journal-title":"J Investig Dermatol"},{"issue":"1","key":"3526_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.celrep.2014.02.036","volume":"7","author":"J Thorburn","year":"2014","unstructured":"Thorburn J, Andrysik Z, Staskiewicz L, Gump J, Maycotte P, Oberst A, Green DR, Espinosa JM, Thorburn A (2014) Autophagy controls the kinetics and extent of mitochondrial apoptosis by regulating PUMA levels. Cell Rep 7(1):45\u201352. \n                    https:\/\/doi.org\/10.1016\/j.celrep.2014.02.036","journal-title":"Cell Rep"},{"issue":"12","key":"3526_CR22","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.4161\/auto.22145","volume":"8","author":"W He","year":"2012","unstructured":"He W, Wang Q, Xu J, Xu X, Padilla MT, Ren G, Gou X, Lin Y (2012) Attenuation of TNFSF10\/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1\/RIP1-mediated MAPK8\/JNK activation. Autophagy 8(12):1811\u20131821. \n                    https:\/\/doi.org\/10.4161\/auto.22145","journal-title":"Autophagy"},{"issue":"6","key":"3526_CR23","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/onc.2008.441","volume":"28","author":"DD Li","year":"2009","unstructured":"Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, Wang Y, Xia LP, Feng GK, Liu QQ, Huang WL, Zeng YX, Zhu XF (2009) The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agentsinduced autophagy in cancer cells. Oncogene 28(6):886\u2013898. \n                    https:\/\/doi.org\/10.1038\/onc.2008.441","journal-title":"Oncogene"},{"issue":"7","key":"3526_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.4161\/auto.6.7.13038","volume":"6","author":"W Hou","year":"2010","unstructured":"Hou W, Han J, Lu C, Goldstein LA, Rabinowich H (2010) Autophagic degradation of active caspase-8: a crosstalk mechanism between autophagy and apoptosis. Autophagy 6(7):891\u2013900. \n                    https:\/\/doi.org\/10.4161\/auto.6.7.13038","journal-title":"Autophagy"},{"key":"3526_CR25","first-page":"6623","volume":"35","author":"Z Zhivko","year":"2010","unstructured":"Zhivko Z, Donika I, Ichio A TSUNEO SAGA and RUMIANA BAKALOVA (2010) 2-Deoxy-D-glucose sensitizes cancer cells to barasertib and everolimus by ROS-independent mechanism(s). Anticancer Res 35: 6623\u20136632","journal-title":"Anticancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3526-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T03:35:57Z","timestamp":1548905757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3526-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3526-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"16 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author Yuting Xu declares that she has no conflict of interest. Author Qingling Wang declares that she has no conflict of interest. Author Lin Zhang declares that she has no conflict of interest. Author Maojin Zheng declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}